Skip to search formSkip to main contentSkip to account menu

Dolutegravir:Susc:Pt:Isolate:OrdQn:Genotyping

Known as: Dolutegravir [Susceptibility] by Genotype method, Dolutégravir [Sensibilité] Isolat ; Alphanumérique ; Génotypage, Dolutégravir:Sensibilité:Ponctuel:Isolat:Alphanumérique:Génotypage 
National Institutes of Health

Related topics

Related topics

3 relations
Genotype determinationIsolate - microorganismdolutegravir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-Existing NRTI Resistance.
BACKGROUND Study 4030 was a phase 3, randomized, double-blinded study of 565 HIV-1 RNA suppressed participants switching to… 
2019
2019
Bedeutung der Single-Tablets ungebrochen
  • Marco Mrusek
  • MMW - Fortschritte der Medizin
  • 2019
  • Corpus ID: 145938708
_ Single-Tablet-Regime sind in der HIVerapie essenziell für den Behandlungserfolg, betonte Dr. Jonathan Cartledge, HIVerapeut vom… 
2017
2017
Zulassungserweiterung für Dolutegravir
  • Red.
  • MMW - Fortschritte der Medizin
  • 2017
  • Corpus ID: 199373770
_ Die randomisierte, placebokontrollierte C-EDGE-CO-STAR-Studie [Dore GJ et al. Ann Intern Med. 2016;165:625– 34] war die erste… 
Highly Cited
2016
Highly Cited
2016
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia.
BACKGROUND Reducing drug burden is a key challenge for achieving lifelong suppressive HIV therapy. Dolutegravir, with a high… 
2016
2016
Dolutegravir Monotherapy as Treatment De-Escalation in HIV-Infected Adults with Virological Control: DoluMono Cohort Results
Background The potential toxicity of long-term anti-retroviral therapy (ART) requires ongoing investigation of novel strategies… 
2016
2016
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals
Background: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed… 
2015
2015
Dolutegravir zeichnet sich durch eine hohe Resistenzbarriere aus
Mit Verordnen allein ist es nicht getan So seien Patienten aus unterschiedlichen Gründen nicht in der Lage, ihre HIV-Medikamente… 
Highly Cited
2013
Highly Cited
2013
Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase
ABSTRACT Drug resistance mutations (DRMs) have been reported for all currently approved anti-HIV drugs, including the latest… 
Highly Cited
2010
Highly Cited
2010
Soybean sudden death syndrome species diversity within north and South america revealed by multilocus genotyping.
Sudden death syndrome (SDS) of soybean has become a serious constraint to the production of this crop in North and South America… 
Highly Cited
1998
Highly Cited
1998
Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)